enfortumab,erdafitinib,pembrolizumab
astellas,seagen,merck,janssen
['ev-302', 'pembro', 'erda ']
 i'll be curious to see the response rate to ev+pembro in ev-302 among fgfr2/3 altered pts. erda +/- pd-1 could be tough to tolerate in the real-world setting, but might be a reasonable 1l option for carefully selected pts
Medical Oncologist @TexasOncology & @TheUSONetwork - focused on GU cancers and clinical trials - former @MSKCancerCenter @NYULangone - tweets are my own